Moreover, in the setting of advanced HF with the use of cardiac resynchronization therapy, IL-1β levels were predictive of the primary outcome (HF hospitalization-free survival with a decrease in end-systolic volume of at least 15%) at 12 months on univariate analysis, with the significance fading upon adjustments [46]. This evidence concerns the gene IL1B and hydrops fetalis.